{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"35.0"},{"groupId":"OG002","value":"33.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"427"},{"groupId":"OG001","value":"289"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"Participants were considered post-baseline ATA positive if they had post-baseline ATAs to Atezolizumab that were treatment-induced or treatment-enhanced. Participants had treatment-induced ATAs if they had a baseline-negative ATA result and developed ATAs at any time after initial drug administration. Participants had treatment-enhanced ATAs if they had a baseline-positive ATA result that showed an enhanced signal that was \\>/= 0.60 titer units at any time after initial drug initiation.","groups":[{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG000","title":"Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG001","title":"IC1/2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG002","title":"IC2/3 Atezolizumab"}],"paramType":"NUMBER","populationDescription":"ATA evaluable population is defined as patients who received atezolizumab treatment and had at least one post-treatment ATA result.","reportingStatus":"POSTED","timeFrame":"Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)","title":"Percentage of Participants With Post-Baseline Anti-therapeutic Antibodies (ATA) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}